Supernus Pharmaceuticals, Inc. (SUPN) Balance Sheet

The balance sheet has expanded modestly over the past ten quarters, with total assets increasing by approximately 7.7% from 2024Q1 to 2026Q2. Equity has grown from $929.2M to $1.0B, driven by retained earnings accumulation despite recent net losses. This suggests the company is funding its investment phase through internal cash generation and modest debt, rather than dilutive equity issuance, which supports a stable financial foundation.

Supernus carries negligible debt relative to equity, with a debt-to-equity ratio of just 0.04 and debt-to-assets of approximately 2.9%. This low leverage appears strategic, providing ample borrowing capacity for future acquisitions or operational needs. The stability of debt levels around $40M over the past year suggests no refinancing pressure, and interest coverage is likely robust given the company's cash generation, though recent operating losses warrant monitoring.

The asset mix is heavily weighted toward intangibles and goodwill, which together represent a significant portion of total assets, consistent with a specialty pharma business model. The jump in PPE in 2026Q2 likely reflects an acquisition, but the overall PPE remains minimal, underscoring an asset-light operation. Goodwill has been stable, suggesting no impairment concerns to date, but investors should monitor for potential write-downs if acquired businesses underperform.

Equity quality is supported by a substantial retained earnings balance, which has historically been built through profitable operations. However, the recent decline in retained earnings from $517.9M to $457.2M over two quarters indicates that net losses are eroding accumulated profits. The company has not engaged in buybacks or dividends, focusing instead on reinvestment, which may be appropriate given the growth phase, but the trend in retained earnings warrants attention.

The company's liquidity position has improved significantly, with cash more than doubling from $69.3M in 2024Q4 to $180.0M in 2026Q2. The current ratio of 2.08 indicates a comfortable buffer against short-term obligations, though it is lower than the 2.58 seen in 2025Q2. This cash build provides a cushion for ongoing operating losses and potential strategic investments, but the recent operating cash flow volatility suggests that liquidity could fluctuate.